Alector concludes enrolment in Phase II trial of Alzheimer’s treatment
Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the efficacy and safety …
Post
-
-
Kyoto University, CiRA trial of iPS therapy shows promise in Parkinson’s
A Phase I/II trial by Japan’s Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) researcher …
-
Advarra announces eIRB and Study Collaboration integration for trials
Advarra has integrated its electronic institutional review board (eIRB) system, known as Center for IRB Intelligence (CIRBI), with its single-sign-on-enabled …
-
ESCMID Global 2025: Sex differences in patients with serious bacterial infections
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference held in Vienna, Austria from 11 …
-
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels …
-
ESCMID Global 2025: The challenges of eliminating viral hepatitis
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, held from 11 …
-
ESCMID Global 2025: The challenges of eliminating viral hepatitis
At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, held from April …
-
WHO warns that polio cases are on the rise
The World Health Organization (WHO) has released an update on polio following the March 2025 meeting of the International Health …
-
Northwestern University enrols first subject in trial of drug for pericarditis
Northwestern University in Illinois, US, has enrolled the first subject in a Phase III trial of Cardiol Therapeutics' drug candidate, …
-
Cullinan Therapeutics receives EMA approval for rheumatoid arthritis drug trial
The European Medicines Agency (EMA) has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid …
-
Sabin Vaccine Institute begins trial of vaccine candidate for Marburg virus disease
The Sabin Vaccine Institute has begun a Phase II trial in the US to evaluate its Marburg vaccine, with the …
-
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical …
-
Podcast: What’s next for the pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans …
-
Analysis tracks condition of patients recovered from Omicron Covid-19 infection
Among the myriad strains of Covid-19 infection that have emerged since the outset of the pandemic, variants branching from the …
-
Hoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritus
US-based biopharmaceutical company Hoth Therapeutics has reported interim data from a Phase IIa trial of HT-001, a drug designed for …
